Abstract

Given the evolution of our epidemiology and the predominance of non-vaccine serotypes (non-PCV15) in Belgium, the effect of PCV13 or PCV15 vaccines can be expected to be comparable in the target group. 

On this basis, the SHC currently recommends, without preference, PCV13 or PCV15 over PCV10.

This report is only available in Dutch and French.

  • Recommendation
  • Europe
  • Belgium
  • Children
  • Adolescents
  • Pneumococcal disease